Degradation of blood group A glycolipid A-6-2 by normal and mutant human skin fibroblasts

Journal of Lipid Research

Volumn 39, Issue 9, 1998, Pages 1768-1780

  Asfaw, Befekadu ^a   Schindler, Detlev ^b   Ledvinová, Jana ^a   Černý, Bohuslav ^a   Šmíd, František ^a   Conzelmann, Ernst ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Fibroblasts; Fucosidase; In situ metabolism; Schindler disease; Sphingolipid activator proteins; N acetylgalactosaminidase deficiency

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; BLOOD GROUP A ANTIGEN; GLYCOLIPID;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GM2 GANGLIOSIDOSIS; HUMAN; HUMAN CELL; LYSOSOME STORAGE DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN FIBROBLAST; TAY SACHS DISEASE;

EID: 0031711605     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Watkins, W. M. 1980. Biochemistry and genetics of the ABO, Lewis and P blood group systems. In Advances in Human Genetics, Vol. 10. H. Harris and K. Hirschhorn, editors. Plenum Press, New York, 1-136.
2. Schenkel-Brunner, H. 1995. Human Blood Groups. Chemical and Biochemical Basis of Antigen Specificity. Springer Verlag, Vienna.
3. Desnick, R. J., Y. A. Ioannou, and C. M. Eng. 1993. α-Galactosidase A deficiency: Fabry disease. In The Metabolic Basis of Inherited Disease. 7th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, editors. McGraw-Hill, New York. 2741-2784.
4. Ledvinová, J., H. Poupětová, A. Hanáčková, M. Písačka, and M. Elleder. 1997. Blood group B glycosphingolipids in α-galactosidase deficiency (Fabry disease): influence of secretor status. Biochim. Biophys. Acta. 1345: 180-187.
5. Desnick, R. J., and A. M. Wang. 1995. α-N-Acetylgalactosaminidase deficiency: Schindler disease. In The Metabolic Basis of Inherited Disease. 7th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, editors. McGraw-Hill, New York. 2509-2528.
6. Schindler, D., D. F. Bishop, D. E. Wolfe, A. M. Wang, H. Egge, R. U. Lemieux, and R. J. Desnick. 1989. Neuroaxonal dystrophy due to lysosomal α-N-acetylgalactosaminidase deficiency. N. Engl. J. Med. 320: 1735-1740.
7. Klima, B., G. Pohlentz, D. Schindler, and H. Egge. 1992. An investigation into the glycolipid metabolism of α-N-acetylgalactosaminidase-deficient fibroblasts using native and artificial glycolipids. Biol. Chem. Hoppe-Seyler. 373: 989-999.
8. Holgersson, J., M. E. Breimer, and B. E. Samuelson. 1992. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. APMIS. 100 (Suppl. 27): 18-27.
9. Koscielak, J., H. Miller-Podraza, and E. Zdebska. 1978. Isolation of poly(glycosyl)ceramides with A, B, H and I blood-group activities. Methods Enzymol. 50: 211-216.
10. Hakomori, S-I. 1978. Isolation of blood group ABH-active glycolipids from human erythrocyte membranes. Methods Enzymol. 50: 207-211.
11. Ledeen, R. W., and R. K. Yu. 1982. Gangliosides: structure, isolation and analysis. Methods Enzymol. 83: 139-191.
12. Schnaar, R. L. 1994. Isolation of glycosphingolipids. Methods Enzymol. 230: 348-370.
13. Evans, E. A. 1974. Tritium and Its Compounds. 2nd edition. Butterworths, London.
14. Hanuš, J. 1969. Czechoslovakia patent 133272. Chem. Abstr. 73: 82991t (1970).
15. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
16. Wenger, D. A., and C. Williams. 1991. Screening for lysosomal disorders. In Techniques in Diagnostic Human Biochemical Genetics. Laboratory Manual. E. Holmes, editor. Wiley-Liss, Inc., New York. 587-617.
17. M2 gangliosidosis, and for its subcellular localization. Hoppe-Seyler's Z. Physiol. Chem. 365: 347-356.
18. Legler, G. 1977. Glucosidases. Methods Enzymol. 46: 368-381.
19. Stevens, R. L., A. L. Fluharty, H. Kihara, M. M. Kaback, L. J. Shapiro, B. Marsh, K. Sandhoff, and G. Fischer. 1981. Cerebroside sulfatase activator deficiency-induced metachromatic leukodystrophy. Am. J. Hum. Genet. 33: 900-906.
20. Harzer, K., B. C. Paton, A. Poulos, B. Kustermann-Kuhn, W. Roggendorf, T. Grisar, and M. Popp. 1989. Sphingolipid activator protein (SAP) deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur. J. Pediatr. 149: 31-39.
21. Nakano, T., K. Sandhoff, J. Stümper, H. Christomanou, and K. Suzuki. 1989. Structure of full-length cDNA coding for sulfatide activator, a co-β-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J. Biochem. (Tokyo) 105: 152-154.
22. Rorman, E. G., and G. A. Grabowski. 1989. Molecular cloning of a human co-β-glucosidase cDNA - evidence that four sphingolipid activator proteins are encoded by single genes in humans and rats. Genomics. 5: 486-492.
23. Jacquemin-Sablon, H., L. Ganz, and J. Feunteun. 1990. Transfer of immortality by transfection of genomic DNA from SV40 established cell lines into rat embryo fibroblasts. Biol. Cell. 68: 227-230.
24. M1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders. Hum. Genet. 89: 513-518.
25. Schwarzmann, G., P. Hoffmann-Bleihauer, J. Schubert, K. Sandhoff, and D. Marsh. 1983. Incorporation of ganglioside analogues into fibroblast cell membranes. A spin label study. Biochemistry. 22: 5041-5048.
26. M2 gangliosidosis subjects. Eur. J. Biochem. 149: 247-255.
27. Porter, M. T., A. L. Fluharty, J. Trammell and H. Kihara. 1971. A correlation of intracellular cerebroside sulfatase activity in fibroblasts with latency in metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 44: 660-666.
28. Leinekugel, P., S. Michel, E. Conzelmann, and K. Sandhoff. 1992. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. 88: 513-523.
29. Kihara, H., C-K. Ho, A. L. Fluharty, K. K. Tsay, and P. L. Hartlage. 1980. Prenatal diagnosis of metachromatic leukodystrophy in a family with pseudo arylsulfatase A deficiency by the cerebroside sulfate loading test. Pediatr. Res. 14: 224-227.
30. Radsak, K., G. Schwarzmann, and H. Wiegandt. 1982. Studies on the cell association of exogenously added sialo-glycolipids. Hoppe-Seyler's Z. Physiol. Chem. 363: 263-272.
31. Mahley, R. W., and T. L. Innerarity. 1983. Lipoprotein receptors and cholesterol homeostasis. Biochim. Biophys. Acta. 737: 197-222.
32. Mahley, R. W., T. L. Innerarity, S. C. Rall, and K. H. Weisgraber. 1984. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 25: 1277-1294.
33. Conzelmann, E., and K. Sandhoff. 1983/84. Residual activities and the development of neurological disorders. Dev. Neurosci. 6: 58-71.
34. A2 by hexosaminidase A. Hoppe-Seyler's Z. Physiol. Chem. 360: 1837-1849.
35. Sandhoff, K. 1969. Variation of β-N-acetylhexosaminidase-pattern in Tay-Sachs disease. FEBS Lett. 4: 351-354.
36. M2 gangliosidoses. In The Metabolic Basis of Inherited Disease. 6th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, editors. McGraw-Hill, New York. 1807-1839.
37. Sandhoff, K., K. Harzer, W. Wässle, and H. Jatzkewitz. 1971. Enzyme alterations and lipid storage in three variants of Tay-Sachs disease. J. Neurochem. 18: 2469-2489.
38. A2. Purification of the enzymes by affinity chromatography employing specific elution. Hoppe-Seyler's Z. Physiol. Chem. 358: 779-787.
39. Sandhoff, K., K. Harzer, and W. Fürst. 1995. Sphingolipid activator proteins. In The Metabolic Basis of Inherited Disease. 7th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, editors. McGraw-Hill, New York. 2427-2441.
40. M1-ganglioside hydrolysis - probable identity on the basis of their co-purification, properties, ligand binding and immunochemical interactions. Glycoconjugate J. 4: 157-170.
41. M1 and globotriaosylceramide. Arch. Biochem. Biophys. 259: 627-638.
42. Li, S-C., H. Kihara, S. Serizawa, Y-T. Li, A. L. Fluharty, J. S. Mayes, and L. J. Shapiro. 1985. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. J. Biol. Chem. 260: 1867-1871.
43. Harzer, K. 1978. The two human lactosylceramidases and their respective enzyme activity deficiency diseases: inhibition studies using p-nitrophenyl-β-D-galactoside. Hum. Genet. 41: 341-345.
44. Inui, K., and D. A. Wenger. 1982. Properties of a protein activator of glycosphingolipid hydrolysis isolated from the liver of a patient with GM1 gangliosidosis, type 1. Biochem. Biophys. Res. Commun. 105: 745-751.
45. Bradová, V., F. Šmíd, B. Ulrich-Bott, W. Roggendorf, B. C. Paton, and K. Harzer. 1993. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum. Genet. 92: 143-152.
46. Chatelut, M., K. Harzer, H. Christomanou, J. Feunteun, M-T. Pieraggi, B. C. Paton, Y. Kishimoto, J. S. O'Brien, J-P. Basile, J-C. Thiers, R. Salvayre, and T. Levade. 1997. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies. Clin. Chim. Acta. 262: 61-76.